Maddipati Krishna Rao
Department of Pathology, Wayne State University, Detroit, MI, United States.
Front Immunol. 2020 Oct 7;11:580117. doi: 10.3389/fimmu.2020.580117. eCollection 2020.
Many small molecules (mostly lipids derived from polyunsaturated fatty acids) and proteins (e. g., cytokines and chemokines) are labeled as inflammatory mediators for their role in eliciting physiological responses to injury. While acute inflammatory events are controlled by anti-inflammatory drugs, lasting damage to the tissues as a result of persistent inflammation is increasingly viewed as the root cause of many chronic diseases that include cardiovascular, neurological, and metabolic disorders, rheumatoid arthritis, and cancer. Interestingly, some of the "inflammatory" mediators also participate in normal developmental physiology without eliciting inflammation. Anti-inflammatory drugs that target the biosynthesis of these mediators are too indiscriminate to distinguish their two divergent physiological roles. A more precise definition of these two physiological processes partaken by the "inflammatory" mediators is warranted to identify their differences. The new paradigm is named "" ('ə'əə) to distinguish from inflammation and to identify appropriate intervention strategies to mitigate inflammation associated pathophysiology without affecting the normal developmental physiology.
许多小分子(主要是源自多不饱和脂肪酸的脂质)和蛋白质(如细胞因子和趋化因子)因其在引发对损伤的生理反应中的作用而被标记为炎症介质。虽然急性炎症事件可通过抗炎药物得到控制,但持续炎症导致的组织长期损伤越来越被视为许多慢性疾病的根本原因,这些慢性疾病包括心血管疾病、神经疾病和代谢紊乱、类风湿性关节炎以及癌症。有趣的是,一些“炎症”介质也参与正常的发育生理过程而不引发炎症。针对这些介质生物合成的抗炎药物过于不加区分,无法区分它们两种不同的生理作用。有必要对“炎症”介质所参与的这两个生理过程进行更精确的定义,以识别它们的差异。这种新范式被命名为“('ə'əə)”,以区别于炎症,并确定适当的干预策略,以减轻与炎症相关的病理生理学,同时不影响正常的发育生理过程。